Moreover, 102-5 anti-CLPTM1L treatment also inhibit p-Akt (T308) and 3-D spheroid formation in lung cancer cell lines (A549, NCI-H520, NCI-H226) (Supplementary Fig. 5a–c) and in pancreatic cancer cell lines (Panc1, MiaPaca2, and Capan2), (Supplementary Fig. 5d–f). Here, CLPTM1L is linked to lung carcinoma.